If you have been reading about 研究代号 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
antioncogene A gene which helps to regulate cell growth and suppress tumors when functioning correctly, such that its absence or malfunction can result in uncontrolled cell growth and possibly cancer. Compare oncogene.
Loss-of-function mutations, also called inactivating mutations, result in the gene product having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (null allele), it is often called an amorph or amorphic mutation in Muller's morphs schema. Phenotypes associated with such mutations are most often recessive. Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haploinsufficiency). Examples of diseases caused by a loss-of-function mutation include Gitelman syndrome and cystic fibrosis. Gain-of-function mutations also called activating mutations, change the gene product such that its effect gets stronger (enhanced activation) or even is superseded by a different and abnormal function. When the new allele is created, a heterozygote containing the newly created allele as well as the original will express the new allele; genetically this defines the mutations as dominant phenotypes. Several of Muller's morphs correspond to the gain of function, including hypermorph (increased gene expression) and neomorph (novel function). Dominant negative mutations (also called anti-morphic mutations) have an altered gene product that acts antagonistically to the wild-type allele. These mutations usually result in an altered molecular function (often inactive) and are characterized by a dominant or semi-dominant phenotype.
== Early life == Born William Beckett on 10 September 1826, he was the third and second surviving son of Sir Edmund Beckett, 4th Baronet, of Grimthorpe, Yorkshire, and his wife Maria Beverley, daughter of William Beverley of Beverley. He was educated at Rugby School and Trinity College, Cambridge.
Sources: en.wikipedia.org
=== Bjerknes feedback === The close relationship between ocean temperatures and the strength of the trade winds was first identified by Jacob Bjerknes in 1969. Bjerknes also hypothesized that ENSO was a positive feedback system where the associated changes in one component of the climate system (the ocean or atmosphere) tend to reinforce changes in the other. This process is known as Bjerknes feedback. For example, during the growth of El Niño, the reduced contrast in ocean temperatures across the Pacific results in weaker trade winds, further reinforcing the El Niño state. Although these associated changes in the ocean and atmosphere often occur together, the state of the atmosphere may resemble a different ENSO phase than the state of the ocean or vice versa. Because their states are closely linked, the variations of ENSO may arise from changes in both the ocean and atmosphere and not necessarily from an initial change of exclusively one or the other. Conceptual models explaining how ENSO operates generally accept the Bjerknes feedback hypothesis. However, ENSO would perpetually remain in one phase if Bjerknes feedback were the only process occurring. Several theories have been proposed to explain how ENSO can change from one state to the next despite the positive feedback. These explanations broadly fall under two categories. In one view, the Bjerknes feedback naturally triggers negative feedbacks that end and reverse the abnormal state of the tropical Pacific.
This involves inspection of a polished slice of a material to determine the density of "track" markings left in it by the spontaneous fission of uranium-238 impurities. The uranium content of the sample has to be known, but that can be determined by placing a plastic film over the polished slice of the material, and bombarding it with slow neutrons. This causes induced fission of 235U, as opposed to the spontaneous fission of 238U. The fission tracks produced by this process are recorded in the plastic film. The uranium content of the material can then be calculated from the number of tracks and the neutron flux. This scheme has application over a wide range of geologic dates. For dates up to a few million years micas, tektites (glass fragments from volcanic eruptions), and meteorites are best used. Older materials can be dated using zircon, apatite, titanite, epidote and garnet which have a variable amount of uranium content. Because the fission tracks are healed by temperatures over about 200 °C the technique has limitations as well as benefits. The technique has potential applications for detailing the thermal history of a deposit.
=== Incel slang === Clavicular is primarily recognized for introducing language and slang from the incelosphere and manosphere to mainstream society. Peters transformed quickly from an "obscure online presence" into one of the internet's "most inescapable figures" by transforming "chaos into content" and running it through his various "clip accounts". Miami New Times says, "His traditionally handsome face and natural charisma, punctuated by increasingly bizarre moments that feel distinctly internet-era, have turned him into one of livestreaming's most compulsively watchable figures." NBC's Saturday Night Live mocks him, CBS's 60 Minutes interviews him (as does Sean Hannity). The New York Times profiled him and the Hulu looksmaxxing documentary "IMPACT x Nightline: Looksmaxxed" focuses on him. Lingo Peters popularizes has "seeped into the public consciousness" with slang words like "mogging" and the suffix "maxxing" gaining widespread use.
Sources: en.wikipedia.org
== Phase 2 == The second phase of the Protein Structure Initiative (PSI-2) lasted from July 2005 to June 2010. Its goal was to use methods introduced in PSI-1 to determine a large number of proteins and continue development in streamlining the structural genomics pipeline. PSI-2 had a five-year budget of $325 million provided by NIGMS with support from the National Center for Research Resources. By the end of this phase, the Protein Structure Initiative had solved over 4,800 protein structures; over 4,100 of these were unique.
=== Activated carbon === The term "adsorption" itself was coined by Heinrich Kayser in 1881 in the context of uptake of gases by carbons. Activated carbon is a highly porous, amorphous solid consisting of microcrystallites with a graphite lattice, usually prepared in small pellets or a powder. It is non-polar and cheap. One of its main drawbacks is that it reacts with oxygen at moderate temperatures (over 300 °C (572 °F)).
Despite many advantages that the concept of hypercycles presents, there were also some problems regarding the traditional model formulation using ODEs: a vulnerability to parasites and a limited size of stable hypercycles. In 2012, the first experimental proof for the emergence of a cooperative network among fragments of self-assembling ribozymes was published, demonstrating their advantages over self-replicating cycles. However, even though this experiment proves the existence of cooperation among the recombinase ribozyme subnetworks, this cooperative network does not form a hypercycle per se, so we still lack the experimental demonstration of hypercycles.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.